Vendredi, 15 Décembre 2017
Dernières nouvelles
Principale » Clovis Oncology's cancer drug Rubraca succeeds in key study

Clovis Oncology's cancer drug Rubraca succeeds in key study

19 Juin 2017

Hedge funds and other institutional investors own 97.55% of the company's stock. The firm exchanged a volume of 1.97 million shares at hands. Massachusetts-based State Street has invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). State Street Corp now owns 2,141,663 shares of the biopharmaceutical company's stock worth $95,131,000 after buying an additional 1,035,917 shares during the period. Palo Alto Investors LLC now owns 3,894,963 shares of the biopharmaceutical company's stock worth $247,992,000 after buying an additional 90,875 shares during the last quarter. Federated Investors Inc. PA purchased a new position in Clovis Oncology during the fourth quarter valued at about $641,000. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. New York-based Ghost Tree Ltd Llc has invested 2.35% in Clovis Oncology Inc (NASDAQ:CLVS). FMR LLC now owns 1,816,859 shares of the biopharmaceutical company's stock valued at $115,679,000 after buying an additional 1,327,703 shares during the last quarter. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has "Neutral" rating given on Monday, November 16 by Mizuho. Legal General Gru Plc reported 0% in Clovis Oncology Inc (NASDAQ:CLVS). (CLVS) opened at 59.97 on Friday. About 6.36M shares traded or 307.69% up from the average. The firm's market cap is $2.68 billion.

Clovis Oncology, Inc. has a 50 day moving average of 54.46 and a 200 day moving average of 55.14. Clovis Oncology has a 1-year low of $11.57 and a 1-year high of $74.94.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.43) by $0.10. The business had revenue of $7.05 million during the quarter, compared to analysts' expectations of $6.04 million.

Portugal vs Mexico: VAR not working well - Santos
The veteran forward used one touch to clear goalkeeper Guillermo Ochoa and then easily found the open net. We have a great chance of winning the Confederations Cup because there are still two [group] games left.

CLVS has been the topic of a number of research reports. Morgan Stanley upped their price target on Clovis Oncology from $68.00 to $72.00 and gave the stock an "overweight" rating in a report on Thursday, February 23rd. 769,111 were reported by Goldman Sachs. Piper Jaffray Companies set a $77.00 price target on Clovis Oncology and gave the stock a "buy" rating in a report on Tuesday, March 14th. (The) upped their price target on Clovis Oncology from $44.00 to $75.00 and gave the stock a "neutral" rating in a report on Wednesday, March 15th. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range.

Specifically, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $61.82, for a total transaction of $185,460.00. Following the completion of the transaction, the insider now owns 203,583 shares in the company, valued at $9,647,798.37. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Hsbc Public Ltd Company owns 5,475 shares or 0% of their U.S. portfolio.

Clovis Oncology, Inc.is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.